39 results
8-K
EX-99.1
KA
Kineta Inc
4 Aug 22
Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
4:51pm
and marketable securities will be sufficient to fund its operating expenses early into the first quarter of 2023.
Research and development (R&D) expense … : Research and development expense was $1.1 million compared to $7.3 million for the second quarter of 2021. The decrease in R&D expense
8-K
EX-99.1
KA
Kineta Inc
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
in December 2022.
Research and development (R&D) expense: R&D expenses were $2.7 million for the three months ended June 30, 2023 compared to $3.9 … ended June 30, 2022. The decreases in R&D expenses were primarily due to lower activities for KVA12123 manufacturing and clinical study start up
8-K
EX-99.1
KA
Kineta Inc
14 Nov 22
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:37am
.
Research and development (R&D) expense: Research and development expense was $0.7 million compared to $6.6 million for the third quarter of 2021 … . The decrease in R&D expense was primarily due to the elimination of a significant portion of the Company’s R&D personnel in connection
8-K
EX-99.1
KA
Kineta Inc
11 May 23
Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update
5:20pm
expenses and capital expenditure requirements into early 2025.
Research and development (R&D) expense: R&D expenses were $2.8 million for the three … months ended March 31, 2023 compared to $4.0 million for the three months ended March 31, 2022. The decrease in R&D expenses was primarily due to lower
8-K
EX-99.1
KA
Kineta Inc
13 May 21
Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments
4:00pm
will be hosting our first R&D Day on May 17, 2021 when we will further detail the results of our Phase 1 trial of YTX-7739 in healthy subjects.”
First … for the treatment of dementia with Lewy Bodies, in the second half of 2021.
Yumanity is hosting a virtual R&D Day on May 17, 2021 at 12:00 p.m. EDT
8-K
EX-99.1
q1yvssvmq
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
8-K
EX-99.1
yvryw177pj d52s
12 May 22
Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments
4:52pm
8-K
EX-99.1
5tzd d0tomyd7
12 Aug 21
Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
4:21pm
8-K
EX-99.1
xmfrygvrzks0m5hawgbo
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
8-K
EX-99.1
xaz9qtdb u4
15 May 24
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
4:03pm
425
EX-99.3
mxq66v2u3swbn 75o7
24 Aug 20
Business combination disclosure
5:28pm
8-K
EX-99.3
lkh859um3n7
24 Aug 20
Yumanity Therapeutics and Proteostasis Therapeutics Announce
5:31pm
8-K
EX-99.1
0td wgdusor2y
24 Mar 22
Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments
4:21pm
425
ke0n501h91y
14 Nov 22
Business combination disclosure
8:50am
8-K
EX-99.1
37i14ktdg7 z1ms
31 Mar 23
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.3
kmiythe26qel
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.2
6e9q31gvt6z2 neb
24 Aug 20
Yumanity Therapeutics and Proteostasis Therapeutics Announce
5:31pm
8-K
EX-99.1
8px tbomu10a0
11 Jan 21
Regulation FD Disclosure
6:30am
8-K
EX-99.3
jr41spnb6w9
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
425
EX-99.2
9pz8d71y3n3q
24 Aug 20
Business combination disclosure
5:28pm